DUBLIN, Calif., June 6 /PRNewswire-FirstCall/ -- SuperGen, Inc. today announced that a contract has been executed to terminate the distribution of Nipent(R) (pentostatin for injection) by Wyeth and transition distribution to SuperGen, Inc. The Company paid Wyeth a $2.1 million dollar early termination fee, making it effective June 1, 2006. SuperGen and Wyeth will collaborate to ensure uninterrupted distribution services during the transition period. Distribution and marketing for Nipent in Europe will be managed by SuperGen’s subsidiary, EuroGen Pharmaceuticals Limited, which is based in Cheltenham, United Kingdom.
EuroGen will have a commercial presence at the upcoming European Hematology Association (EHA) meeting in Amsterdam, The Netherlands. Additionally Nipent will be discussed within a symposium on June 15 at EHA entitled “M.D. Anderson Cancer Center Approach to Patients with Hematological Malignancies,” chaired by Michael J. Keating, M.D.
About Nipent
Nipent(R) (pentostatin for injection) is currently approved as a single- agent treatment for patients with Hairy Cell Leukemia in the United States and selective counties within Europe, and is not approved as either a single agent or as part of a combination regimen for treatment for any other indication in any territory.
About SuperGen
Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. SuperGen’s portfolio includes Orathecin(TM) (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent(R) (pentostatin for injection), Mitomycin, and Surface Safe(R) cleaner. In addition, a number of aurora-A, tyrosine kinase and DNA methyltransferase inhibitors are under development. For more information about SuperGen, please visit http://www.supergen.com.
Contacts: SuperGen Noonan Russo Timothy L. Enns Sharon Weinstein S.V.P., Corporate Communications Director of Investor Relations & Business Development Tel: (925) 560-0100 x111 Tel: (212) 845-4271 E-mail: tenns@supergen.com E-mail: sharon.weinstein@eurorscg.com
SuperGen, Inc.
CONTACT: Timothy L. Enns S.V.P., Corporate Communications & BusinessDevelopment for SuperGen, +1-925-560-0100 x111, tenns@supergen.com; orSharon Weinstein, Director of Investor Relations of Noonan Russo forSuperGen, +1-212-845-4271, sharon.weinstein@eurorscg.com
Web site: http://www.supergen.com/
